Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole-Reference-Cited by-同舟云学术

Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole

Published:2008-11 Issue:4 Volume:35 Page:264-270
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Seidegård Janeric,Nyberg Lars,Borgå Olof

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference22 articles.

1. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease;Edsbäcker;Clin. Pharmacokinet.,2004

2. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules Aliment;Edsbäcker;Pharmacol. Ther.,2003

3. Expression of a multidrug-resistance gene in human tumors and tissues;Fojo;Proc. Natl. Acad. Sci. U.S.A.,1987

4. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin;Fromm;Hepatology,1996

5. Molecular and physical mechanisms of first-pass extraction;Hall;Drug. Metab. Dispos.,1999

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn’s Disease Patients through PBPK Modeling;Pharmaceutics;2023-08-30

2. Physiologically based biopharmaceutics modeling of regional and colon absorption in humans;European Journal of Pharmaceutics and Biopharmaceutics;2023-05

3. Using naso- and oro-intestinal catheters in physiological research for intestinal delivery and sampling in vivo: practical and technical aspects to be considered.;The American Journal of Clinical Nutrition;2021-05-24

4. Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network;Advanced Drug Delivery Reviews;2021-04

5. Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling;European Journal of Pharmaceutical Sciences;2021-02